Stock Analyzation: Pfizer's acqusition King Pharmaceuticals - PowerPoint PPT Presentation

pfizer to purchase king pharmaceuticals l.
Skip this Video
Loading SlideShow in 5 Seconds..
Stock Analyzation: Pfizer's acqusition King Pharmaceuticals PowerPoint Presentation
Download Presentation
Stock Analyzation: Pfizer's acqusition King Pharmaceuticals

play fullscreen
1 / 8
Download Presentation
Stock Analyzation: Pfizer's acqusition King Pharmaceuticals
171 Views
Download Presentation

Stock Analyzation: Pfizer's acqusition King Pharmaceuticals

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Pfizer to Purchase King Pharmaceuticals News from October 14, 2010 – Pharmtech Newsletter Magda Neumann – Alina Sachapow – Kasey Navita Phifer [ January 4, 2011 ] www.kNavita.com

  2. News Details • Pfizer produces pharmaceuticals (Viagra, Lipitor, Celebrex) • Announcement of Purchase: Oct. 12, 2010 • $3.6 billion cash • Pfizer paid $14.25 per share (40% higher than closing price) • Top two Pfizer drug patents (Lipitor & Xalatan) expire 2011 • Purchased Wyeth in early 2009 Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  3. Financials of the News Numbers in billions of USD*Share Price NOT in billions Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  4. Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  5. Theoretical Linkages • Chapter 7 • Technical analysis - Trends, volume, OBV, MACD, SMA • Fundamental analysis - Background information • Valuation by comparables Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  6. Conclusion • Purchase of King less dramatic than Wyeth • Tactical desicion regarding expiring patents, falling stock prices & growing competition • Stock price still low (compared to $50 earlier) Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ]

  7. Resources • Brealey/Myers/Marcus, Fundamentals of Corporate Finance, 6th Edition, McGraw-Hill, 2009 [Chapter 7] • http://www.wikinvest.com/stock/Pfizer_(PFE)/Generic%20Competition (accessed 21.11.2010) • http://de.finance.yahoo.com/echarts?s=PFE#symbol=pfe;range=2y;compare=;indicator=volume;charttype=area;crosshair=on;ohlcvalues=0;logscale=off;source=undefined; (accessed 15.11.2010) • http://www.wikinvest.com/stock/Pfizer_(PFE)/Generic%20Competition (accessed 21.11.2010) • http://drugdelivery.pharmaceutical-business-review.com/news/pfizers_q4_revenue_decreases_290109 (accessed 21.11.2010) • http://www.wikinvest.com/stock/Pfizer_(PFE)/Data/Key_Metrics (accessed 21.11.2010) • http://de.finance.yahoo.com/echarts?s=PFE#chart8 (accessed 15.11.2010) • http://www.marketwatch.com/investing/stock/PFE/charts?countryCode=US&submitted=true&intflavor=advanced&origurl=%2Ftools%2Fquotes%2Fintchart.asp&time=9&freq=1&comp=Enter%20Symbol(s)%3A&compidx=aaaaa~0&compind=aaaaa~0&uf=7168&ma=1&maval=50&lf=1&lf2=4&lf3=8&type=2&size=2&optstyle=1013 (accessed 15.11.2010) • http://www.investopedia.com/university/technical/ (accessed 14.11.2010)

  8. Thank You for Your Attention! Magda Neumann – Alina Sachapow – Navi K. Phifer [ January 4, 2011 ] www.kNavita.com